Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine entities : Dyadic international, inc. save search
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Published: 2023-11-29 (Crawled : 13:30) - globenewswire.com
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: -0.85%
H: 5.71%
C: -2.29%
candidate vaccine trial results
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
Published: 2023-10-05 (Crawled : 12:30) - globenewswire.com
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 5.94%
H: 0.17%
C: -5.61%
award vaccine rapid hospital immunotherapy platform
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Published: 2023-07-24 (Crawled : 12:00) - globenewswire.com
SNY | News | $45.39 47K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 4.84%
H: 4.62%
C: -2.56%
candidate vaccine update protein trial
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: -0.71%
H: 21.43%
C: 20.71%
dyai-100 covid-19 candidate protein vaccine trial update phase 1
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-01-24 (Crawled : 14:20) - biospace.com/
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 5.52%
H: 1.74%
C: -1.17%
dyai-100 covid-19 candidate antibody vaccine trial response
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
Published: 2022-12-14 (Crawled : 14:20) - biospace.com/
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 10.17%
H: 3.85%
C: -5.38%
dyai-100 covid-19 vaccine study
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2022-10-27 (Crawled : 13:00) - globenewswire.com
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 4.65%
H: 0.44%
C: -1.78%
dyai-100 covid-19 candidate vaccine trial approval
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
Published: 2022-10-04 (Crawled : 13:00) - globenewswire.com
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 0.0%
H: 1.56%
C: -7.81%
europe expansion vaccine technology potential influenza
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
Published: 2022-04-13 (Crawled : 13:00) - globenewswire.com
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: -2.0%
H: 13.06%
C: 12.24%
covid-19 biotech vaccine funding india platform license
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
Published: 2022-02-10 (Crawled : 13:30) - globenewswire.com
PAHC | $13.04 1.32% 1.45% 0
|
Health Technology
|
| O: 4.61%
H: 3.54%
C: 1.11%
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: -2.98%
H: 9.46%
C: 0.26%
health license vaccine commercialization
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern
Published: 2021-08-19 (Crawled : 21:00) - globenewswire.com
SRNE | $0.024 -14.29% -8.85% 0
|
Health Technology
|
| O: 0.36%
H: 3.02%
C: 0.85%
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: -1.33%
H: 8.99%
C: 6.07%
covid animals vaccine sars-cov-2
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Published: 2021-08-11 (Crawled : 13:15) - biospace.com/
SRNE | $0.024 -14.29% -8.85% 0
|
Health Technology
|
| O: 0.0%
H: 1.36%
C: 0.68%
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 20.33%
H: 28.7%
C: 22.22%
covid vaccine license technology
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Published: 2021-08-11 (Crawled : 13:00) - globenewswire.com
SRNE | $0.024 -14.29% -8.85% 0
|
Health Technology
|
| O: 0.0%
H: 1.36%
C: 0.68%
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 20.33%
H: 28.7%
C: 22.22%
covid vaccine license technology
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
Published: 2021-06-28 (Crawled : 14:00) - biospace.com/
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 1.63%
H: 4.29%
C: -0.8%
vaccine
Dyadic announces development of COVID-19 Vaccine in IndiaIn collaboration with Syngene International Ltd.
Published: 2021-05-26 (Crawled : 13:15) - biospace.com/
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 10.34%
H: 4.68%
C: -4.45%
covid collaboration india vaccine covid-19
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
Published: 2021-03-29 (Crawled : 13:00) - irdirect.net
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 1.87%
H: 0.92%
C: -3.12%
ISDR | $11.595 0.04% 0.0% 0
|
Technology Services
|
| O: 0.0%
H: 3.91%
C: -2.28%
covid vaccine trial covid-19
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
Published: 2021-03-18 (Crawled : 18:00) - biospace.com/
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: 6.49%
H: 2.16%
C: -6.68%
vaccine trial sars-cov-2
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | News | $1.4 250.0% 35M
|
Finance
ZCMD | $2.18 50.35% 24M
|
Commercial Services
RWOD | $12.0 50.06% 3.9M
|
n/a
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
INDO | $4.9 20.1% 2.2M
|
Energy Minerals
NURO | $4.32 18.36% 66K
|
Health Technology
HUBC | $1.52 17.83% 4.7M
|
n/a
MCB 4 | $38.545 16.45% 34K
|
Finance
BHAT | $1.06 11.58% 9.3K
|
Consumer Durables
Your saved searches
Save your searches and get alerts when important news are released.